Patents Examined by Kamal A. Saeed
  • Patent number: 11123315
    Abstract: The present invention relates to TRPV1 selective agonist compositions including a capsaicinoid, a surfactant and an extended release agent, and to methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: September 21, 2021
    Assignee: Propella Therapeutics, Inc.
    Inventors: Philip J. Birbara, Daniel Bucks
  • Patent number: 11124502
    Abstract: In one aspect, the invention relates to compounds having the formula: where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: September 21, 2021
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes
  • Patent number: 11117867
    Abstract: Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: September 14, 2021
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Yahya El-Kattan, Yarlagadda S. Babu
  • Patent number: 11117888
    Abstract: The invention provides a novel class of propiolylamide-based irreversible inhibitors of PKM2 compounds of the general formula I, pharmaceutical compositions, and methods of inducing an anti-tumor effect in a subject suffering from tumor comprising administering to the subject a pharmaceutical composition comprising an effective amount of compound of formula I.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: September 14, 2021
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventors: Ching-Shih Chen, Hsiang-Wen Lin, Chih-Shiang Chang, Po-Chen Chu
  • Patent number: 11116751
    Abstract: The present invention relates to a blend for prevention, mitigation, or treatment of schizophrenia, the blend containing a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and, more specifically, to a blend and a pharmaceutical composition each containing a carbamate compound of chemical formula 1 and aripiprazole, and to a use thereof for treating schizophrenia.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: September 14, 2021
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Chan Mi Joung, Sun Gwan Hwang, Ji Won Lee, Young Koo Jang
  • Patent number: 11110080
    Abstract: An empirical Screen for Anti-infectives using Fluorescence microscopy of IntracellulaR Enterobacteriaceae (SAFIRE) was developed. Using this methodology, a library of small molecules and identified antimicrobials that are cell permeable and non-host-toxic were screened. Inhibitors of bacterial efflux pumps were identified as being implicated in antibiotic resistance and are attractive therapeutic targets for antimicrobials.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: September 7, 2021
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Abigail L. Reens, Amy L. Crooks, Corrella S. Detweiler
  • Patent number: 11104690
    Abstract: The present invention relates to a compound represented by formula I?: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: August 31, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Dong-Ming Shen, Thomas H. Graham, Wensheng Liu, Clare Tudge, Andreas Verras, Jinlong Jiang
  • Patent number: 11098025
    Abstract: The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitinization of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: August 24, 2021
    Assignee: Montelino Therapeutics, Inc.
    Inventors: Jenny Desantis, Roy Joseph Vaz
  • Patent number: 11096931
    Abstract: The application relates to amide derivatives, processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: August 24, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Stefaan Julien Last, Bart Rudolf Romanie Kesteleyn, Sandrine Céline Grosse, Tim Hugo Maria Jonckers, Jan Martin Berke, Geerwin Yvonne Paul Haché, Edgar Jacoby, Carolina Martinez Lamenca, Morgan Charles R. Lecomte, Abdellah Tahri, Sarah Sauviller, Karen Maria Vergauwen
  • Patent number: 11098037
    Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: August 24, 2021
    Assignee: Fresenius Kabi Oncology Ltd.
    Inventors: Vinod Singh Tomar, Abul Azim, Nitin Gupta, Saswata Lahiri, Walter Cabri
  • Patent number: 11098034
    Abstract: Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: August 24, 2021
    Assignee: ARENA PHARMACEUTICALS, INC.
    Inventors: Thuy-Anh Tran, Jason B. Ibarra, Young-Jun Shin, Brett Ullman, Ning Zou, Xi Zeng
  • Patent number: 11091450
    Abstract: Disclosed herein a crystal structure of a caspase inhibitor, and more specifically a crystal structure of an (S)-3-((S)-2-(5-(2-chlorophenyl)isoxazole-3-formylamide)proponamide)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)valeric acid, a preparation method therefor, a crystal polymer, a pharmaceutical composition and uses thereof. The compound A of formula (I) disclosed herein exhibits high crystal structure stability, low hygroscopicity, and advantageously shows physical properties, safety and metabolic stability while having relatively high pharmaceutical value.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 17, 2021
    Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Inventors: Songliang Wu, Jianfeng Mou, Haiying He
  • Patent number: 11077116
    Abstract: The invention refers to the use of isoxazole derivatives to prepare medicament able to induce fetal hemoglobin (HbF) synthesis in ?-thalassemia and sickle cell disease (SCD) patients.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: August 3, 2021
    Assignee: RARE PARTNERS SRL
    Inventors: Ilaria Lampronti, Roberto Gambari, Daniele Simoni
  • Patent number: 11072586
    Abstract: Solid state forms of Eltrombopag choline, processes for preparation thereof and pharmaceutical compositions thereof are disclosed.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: July 27, 2021
    Assignee: ASSIA CHEMICAL INDUSTRIES LTD.
    Inventors: Sharma Vijay Hariprasad, Nasir Ali Shafakat Ali, Joshi Ashutosh Vijay, Parven Kumar Luthra, Anantha Rajmohan Muthusamy, Amit Singh, Rajesh Sadanand Bate, Sadanand Hardeo Maurya
  • Patent number: 11071300
    Abstract: Compounds of formula (I), as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control pests such as insect, acarine, mollusc and nematode pests.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: July 27, 2021
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: André Jeanguenat, Myriem El Qacemi, André Stoller, Aurelien Bigot, Denis Gribkov
  • Patent number: 11066397
    Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) where the substituents R, R1-R5, k, m, n, and q are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders, infectious disease, or for providing immunosuppression for transplanted organs or tissues.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: July 20, 2021
    Assignee: CORNELL UNIVERSITY
    Inventors: Gang Lin, Carl Nathan, Pradeep K. Singh, Lei Shi, Laura Kirkman
  • Patent number: 11058674
    Abstract: The present invention provides a drug for treating cocaine addiction or preventing the relapse of the same. Specifically, the present invention provides a drug for treating cocaine addiction or preventing the relapse of the same containing (R)-2-{3-[1-(5-methyl-1,2,3,4-tetrahydronaphthalen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: July 13, 2021
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Koji Teshima
  • Patent number: 11059805
    Abstract: The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: July 13, 2021
    Assignee: Beijing Innocare Pharma Tech Co., Ltd.
    Inventors: Xiangyang Chen, Yingxiang Gao, Norman Xianglong Kong
  • Patent number: 11053208
    Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: July 6, 2021
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Choon Ho Ryu, Min Soo Han, Yeo Jin Yoon, Yu Jin Kim, Ka Eun Lee, Ju Young Lee, Myung Jin Jung, Eun Hee Baek, Yu Jin Shin, Eun Ju Choi, Young Soon Kang, Yong Soo Kim, Yea Mi Song, Jin Sung Kim, Hee Jeong Lim
  • Patent number: 11046713
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: June 29, 2021
    Assignee: ORION CORPORATION
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Koivikko, Patrik Holm, Sirpa Rasku, Anniina Vesalainen